GRIFOLS ADR 1/2/EO-50 (F:G0F) — Market Cap & Net Worth
Market Cap & Net Worth: GRIFOLS ADR 1/2/EO-50 (G0F)
GRIFOLS ADR 1/2/EO-50 (F:G0F) has a market capitalization of $4.21 Billion (€3.60 Billion) as of September 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #4006 globally and #712 in its home market, demonstrating a -1.84% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GRIFOLS ADR 1/2/EO-50's stock price €4.26 by its total outstanding shares 844570736 (844.57 Million). Also see GRIFOLS ADR 1/2/EO-50 asset portfolio for a full breakdown of the balance sheet.
GRIFOLS ADR 1/2/EO-50 Market Cap History: 2022 to 2026
GRIFOLS ADR 1/2/EO-50's market capitalization history from 2022 to 2026. Data shows change from $5.13 Billion to $4.50 Billion (-13.39% CAGR). Also see G0F cash flow metrics for how efficiently the company converts equity into cash flow.
GRIFOLS ADR 1/2/EO-50 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GRIFOLS ADR 1/2/EO-50's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check GRIFOLS ADR 1/2/EO-50 (G0F) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.68x
GRIFOLS ADR 1/2/EO-50's market cap is 0.68 times its annual revenue
Latest Price to Earnings (P/E) Ratio
12.77x
GRIFOLS ADR 1/2/EO-50's market cap is 12.77 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $5.13 Billion | $6.06 Billion | $185.03 Million | 0.85x | 27.75x |
| 2023 | $7.31 Billion | $6.59 Billion | $42.00 Million | 1.11x | 173.97x |
| 2024 | $4.23 Billion | $7.21 Billion | $157.00 Million | 0.59x | 26.92x |
| 2025 | $5.13 Billion | $7.52 Billion | $402.00 Million | 0.68x | 12.77x |
Competitor Companies of G0F by Market Capitalization
Companies near GRIFOLS ADR 1/2/EO-50 in the global market cap rankings as of September 19, 2026. Review G0F tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to GRIFOLS ADR 1/2/EO-50 by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #16 globally with a market cap of $1.03 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #20 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #29 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #45 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #16 | Eli Lilly and Company | NYSE:LLY | $1.03 Trillion | $1152.93 |
| #20 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #29 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $269.99 |
| #45 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $263.96 |
GRIFOLS ADR 1/2/EO-50 Historical Marketcap From 2022 to 2026
Between 2022 and today, GRIFOLS ADR 1/2/EO-50's market cap moved from $5.13 Billion to $ 4.50 Billion, with a yearly change of -13.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €4.50 Billion | -12.31% |
| 2025 | €5.13 Billion | +21.50% |
| 2024 | €4.23 Billion | -42.16% |
| 2023 | €7.31 Billion | +42.31% |
| 2022 | €5.13 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of GRIFOLS ADR 1/2/EO-50 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.21 Billion USD |
| MoneyControl | $4.21 Billion USD |
| MarketWatch | $4.21 Billion USD |
| marketcap.company | $4.21 Billion USD |
| Reuters | $4.21 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GRIFOLS ADR 1/2/EO-50
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, u… Read more